arrow
E

Elizabeth A. Dierks

bristol myers squibb
H指数:18
被引数:1,274
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective N-Formyl Peptide Receptor 2 Agonist

从先导化合物到临床候选药物:BMS-986331作为强效且选择性N-甲酰肽受体2激动剂的发现

2026-02-170
PRE
Design; Synthesis; and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408

设计;合成;以及第一类DGKα/ζ抑制剂的T细胞检查点组合潜力 BMS-986408

2025-10-140
PRE
Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent
2024-11-190
PRE
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 Agonists
2024-08-120
PRE
Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
2023-09-191
PRE
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities
2023-05-011
PRE
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity

MGAT2抑制剂可减少小鼠NASH模型中的肝纤维化和炎症,并降低肥胖成人的体重

2022-11-0117
OAAI
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists

甲酰基肽受体2激动剂的杂芳基脲等排物的发现

2022-05-252
OA
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
2021-10-068
PREAI
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
2021-09-0853
PRE
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction

选择性FPR2激动作用可促进重组巨噬细胞表型并改善心肌梗塞后的心脏结构功能

2021-08-0135
OA
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment
2019-12-0139
OAAI
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
2018-01-2724
PREAI
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode
2017-02-0925
PREAI
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors:: Discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent
2008-03-0462
PREAI
The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant
1998-09-0135
OAAI